NO20054140L - Dihydrospiro-[cykloalkyl]-pyrimidonderivat, anvendelser derav for fremstilling av et medikament, medikament omfattende en slik forbindelse, og mellomproduktforbindelse - Google Patents

Dihydrospiro-[cykloalkyl]-pyrimidonderivat, anvendelser derav for fremstilling av et medikament, medikament omfattende en slik forbindelse, og mellomproduktforbindelse

Info

Publication number
NO20054140L
NO20054140L NO20054140A NO20054140A NO20054140L NO 20054140 L NO20054140 L NO 20054140L NO 20054140 A NO20054140 A NO 20054140A NO 20054140 A NO20054140 A NO 20054140A NO 20054140 L NO20054140 L NO 20054140L
Authority
NO
Norway
Prior art keywords
medicament
ring
compound
optionally substituted
dihydrospiro
Prior art date
Application number
NO20054140A
Other languages
English (en)
Other versions
NO20054140D0 (no
Inventor
Alistair William Lochead
Pascal George
Mourad Saady
Franck Slowinski
Philippe Yaiche
Original Assignee
Mitsubishi Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Pharma Corp filed Critical Mitsubishi Pharma Corp
Publication of NO20054140D0 publication Critical patent/NO20054140D0/no
Publication of NO20054140L publication Critical patent/NO20054140L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Oppfinnelsen vedrører et dihydrospiro-[cykloalkyl]-pyrimi-donderivat representert ved formel (I) eller et salt derav: hvori: X representerer to hydrogenatomer, et svovelatom, et oksygenatom eller en C1_2-alkylgruppe og et hydrogenatom; Y representerer en binding, en karbonylgruppe, en metylengruppe som eventuelt er substituert; RI representerer en 2-, 3-eller 4-pyridinring eller en 2-, 4- eller 5-pyrimidinring, idet ringen eventuelt er substituert; R2 representerer en benzenring eller en naftalenring; idet ringene eventuelt er substituert; R3 representerer et hydrogenatom, en C^g-alkyl-gruppe eller et halogenatom; m representerer 1 til 4, n representerer 0 til 3, p representerer 0 til 2, q representerer 0 til 2, idet p + q er lavere enn 4. Oppfinnelsen vedrører også et medikament som omfatter det nevnte derivat eller et salt derav som en aktiv bestanddel som anvendes for forebyggende og/eller terapeutisk behandling av en nevrode-generativ sykdom forårsaket av abnorm aktivitet av GSK3P, slik som Alzheimers sykdom.
NO20054140A 2003-03-07 2005-09-06 Dihydrospiro-[cykloalkyl]-pyrimidonderivat, anvendelser derav for fremstilling av et medikament, medikament omfattende en slik forbindelse, og mellomproduktforbindelse NO20054140L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03290569A EP1454909B1 (en) 2003-03-07 2003-03-07 8'-pyridinyl-dihydrospiro (cycloalkyl) -pyrimido (1,2-a) pyrimidin-6-one and 8'-pyrimidinyl-dihydrospiro (cycloalkyl) pyrimido (1,2-a) pyrimidin-6 derivatives -one and their use against neurodegenerative diseases
PCT/EP2004/003051 WO2004078760A1 (en) 2003-03-07 2004-03-05 SUBSTITUTED 8'-PYRIDINYL-DIHYDROSPIRO-[CYCLOALKYL]-PYRIMIDO [1,2-a] PYRIMIDIN-6-ONE AND 8'-PYRIMIDINYL-DIHYDROSPIRO-[CYCLOALKYL]-PYRIMIDO [1,2-a] PYRIMIDIN-6-ONE DERIVATIVES AND THEIR USE AGAINST NEUROGENERATIVE DISEASES

Publications (2)

Publication Number Publication Date
NO20054140D0 NO20054140D0 (no) 2005-09-06
NO20054140L true NO20054140L (no) 2005-12-02

Family

ID=32799103

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20054140A NO20054140L (no) 2003-03-07 2005-09-06 Dihydrospiro-[cykloalkyl]-pyrimidonderivat, anvendelser derav for fremstilling av et medikament, medikament omfattende en slik forbindelse, og mellomproduktforbindelse

Country Status (26)

Country Link
US (2) US7294632B2 (no)
EP (2) EP1454909B1 (no)
JP (1) JP4639182B2 (no)
KR (1) KR101069984B1 (no)
CN (1) CN100463908C (no)
AR (1) AR043485A1 (no)
AT (1) ATE469153T1 (no)
AU (1) AU2004218250B2 (no)
BR (1) BRPI0408189A (no)
CA (1) CA2516937C (no)
CY (1) CY1111057T1 (no)
DE (1) DE602004027354D1 (no)
DK (1) DK1603915T3 (no)
EA (1) EA008172B1 (no)
ES (1) ES2346311T3 (no)
HK (1) HK1085740A1 (no)
IL (1) IL170461A (no)
MX (1) MXPA05009574A (no)
NO (1) NO20054140L (no)
NZ (1) NZ542135A (no)
PL (1) PL1603915T3 (no)
PT (1) PT1603915E (no)
SI (1) SI1603915T1 (no)
TW (1) TWI320785B (no)
WO (1) WO2004078760A1 (no)
ZA (1) ZA200507107B (no)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1891021B1 (en) 2005-06-14 2019-01-23 Merck Sharp & Dohme Corp. Aspartyl protease inhibitors
EP1928437A2 (en) 2005-08-26 2008-06-11 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
CA2625153A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
AU2006308889A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. GABA receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2382975A3 (en) 2006-05-09 2012-02-29 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
EP1992625A1 (en) * 2007-05-16 2008-11-19 Sanofi-Aventis Arylamide pyrimidone compounds
EP1992621A1 (en) 2007-05-16 2008-11-19 Sanofi-Aventis Heteroarylamide-substituted pyrimidone derivatives for the treatment of neurodegenerative diseases
EP1992624A1 (en) 2007-05-16 2008-11-19 Sanofi-Aventis Heteroarylamide pyrimidone compounds
EP1992620A1 (en) * 2007-05-16 2008-11-19 Sanofi-Aventis Arylamide pyrimidone derivatives for the treatment of neurodegenerative diseases
EP2138494A1 (en) 2008-06-26 2009-12-30 Sanofi-Aventis Substituted alkyl pyrimidin-4-one derivatives
EP2138488A1 (en) 2008-06-26 2009-12-30 sanofi-aventis 4-(pyridin-4-yl)-1H-[1,3,5]triazin-2-one derivatives as GSK3-beta inhibitors for the treatment of neurodegenerative diseases
EP2138492A1 (en) 2008-06-26 2009-12-30 Sanofi-Aventis Substituted pyrimidin-4-one derivatives
EP2138493A1 (en) 2008-06-26 2009-12-30 Sanofi-Aventis Substituted pyrimidone derivatives
EP2138485A1 (en) 2008-06-26 2009-12-30 sanofi-aventis Substituted N-Oxide pyrazine derivatives
EP2138498A1 (en) 2008-06-26 2009-12-30 sanofi-aventis Substituted tricyclic derivatives against neurodegenerative diseases
EP2138495A1 (en) * 2008-06-26 2009-12-30 sanofi-aventis Substituted pyrimido[2,1-a]isoquinolin-4-one derivatives
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
EP2448940B1 (fr) 2009-07-02 2014-05-21 Sanofi Dérivés de 6,7,8,9-tétrahydro-pyrimido{1,2-a} pyrimidin-4-one, leur préparation et leur utilisation pharmaceutique
EP2655375B1 (fr) 2010-12-23 2014-12-03 Sanofi Derives de pyrimidinone, leur preparation et leur utilisation pharmaceutique
FR2992314B1 (fr) 2012-06-22 2015-10-16 Sanofi Sa Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one et 1,2,3,4-tetrahydro-pyrimido{1,2-a}pyrimidin-6-one comportant une morpholine substituee, leur preparation et leur utilisation pharmaceutique
FR2992316A1 (fr) 2012-06-22 2013-12-27 Sanofi Sa Derives de pyrimidinones, leur preparation et leur application en therapeutique
WO2015155738A2 (en) 2014-04-09 2015-10-15 Christopher Rudd Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2812636A1 (fr) * 2000-08-02 2002-02-08 Novapharme Nouveaux derives 2-phenyl imidazo[1.2-a]pyrimidin-5-ones et 2-phenyl 2,3-dihydro imidazo[1,2-a]pyrimidin-5-ones
JP2004507546A (ja) * 2000-09-01 2004-03-11 サノフィ−サンテラボ ２−ピリジニル−６，７，８，９−テトラヒドロピリミド［１，２−ａ］ピリミジン−４−オンおよび７−ピリジニル−２，３−ジヒドロイミダゾ［１，２−ａ］ピリミジン−５（１Ｈ）−オン誘導体
EP1184385A1 (en) * 2000-09-01 2002-03-06 Sanofi-Synthelabo 1-[Alkyl], 1-[(heteroaryl)alkyl] and 1-[(aryl)alkyl]-7-pyridin-4-yl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1H)-one derivatives
EP1184383A1 (en) * 2000-09-01 2002-03-06 Sanofi-Synthelabo 9-[Alkyl], 9-[(heteroaryl)alkyl] and 9-[(aryl)alkyl]-2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one derivatives
PL370349A1 (en) * 2001-09-21 2005-05-16 Sanofi-Aventis Substituted 2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1h)one derivatives
EP1295885A1 (en) * 2001-09-21 2003-03-26 Sanofi-Synthelabo Substituted 2-pyridinyl-6,7,8,9-tetrahydropyrimido(1,2-a)pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo(1,2-a)pyrimidin-5(1H)one derivatives
IL160397A0 (en) * 2001-09-21 2004-07-25 Sanofi Synthelabo Substituted 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido{1,2-a} pyrimidin-4-one and 7-pyrimidinyl-2,3-dihydroimidazo {1,2-a} pyrimidin-5 (1h) one derivatives for neurodegenerative disorders
EP1295884A1 (en) * 2001-09-21 2003-03-26 Sanofi-Synthelabo 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]Pyrimidin-4-one and 7-Pyrimidinyl-2,3-Dihydroimidazo[1,2-a]Pyrimidin-5(1H)one derivatives

Also Published As

Publication number Publication date
HK1085740A1 (en) 2006-09-01
AR043485A1 (es) 2005-08-03
WO2004078760A1 (en) 2004-09-16
MXPA05009574A (es) 2006-05-19
JP2006519814A (ja) 2006-08-31
TWI320785B (en) 2010-02-21
IL170461A (en) 2011-11-30
EP1454909B1 (en) 2008-08-20
JP4639182B2 (ja) 2011-02-23
AU2004218250A1 (en) 2004-09-16
KR20050106500A (ko) 2005-11-09
DK1603915T3 (da) 2010-08-30
CN1777607A (zh) 2006-05-24
PL1603915T3 (pl) 2010-10-29
US20080081819A1 (en) 2008-04-03
KR101069984B1 (ko) 2011-10-04
SI1603915T1 (sl) 2010-08-31
AU2004218250B2 (en) 2010-02-25
US7507743B2 (en) 2009-03-24
DE602004027354D1 (de) 2010-07-08
BRPI0408189A (pt) 2006-03-21
EA008172B1 (ru) 2007-04-27
EP1603915A1 (en) 2005-12-14
ZA200507107B (en) 2006-11-29
CY1111057T1 (el) 2015-06-11
ES2346311T3 (es) 2010-10-14
EP1454909A1 (en) 2004-09-08
CN100463908C (zh) 2009-02-25
EA200501241A1 (ru) 2006-04-28
CA2516937A1 (en) 2004-09-16
ATE469153T1 (de) 2010-06-15
US20060025431A1 (en) 2006-02-02
NZ542135A (en) 2008-06-30
CA2516937C (en) 2011-10-25
PT1603915E (pt) 2010-07-22
NO20054140D0 (no) 2005-09-06
US7294632B2 (en) 2007-11-13
TW200510418A (en) 2005-03-16
EP1603915B1 (en) 2010-05-26

Similar Documents

Publication Publication Date Title
NO20054140L (no) Dihydrospiro-[cykloalkyl]-pyrimidonderivat, anvendelser derav for fremstilling av et medikament, medikament omfattende en slik forbindelse, og mellomproduktforbindelse
NO20054330L (no) 8-substituerte-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-on-derivater
NO20054331L (no) Substituerte-8-perfluoralkyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-on-derivater
WO2007057790A3 (en) Substituted bicyclic pyrimidone derivatives
NO20063187L (no) Substituerte 8'-pyri(mi)dinyl-dihydrospiro-[cykloalkylamin]-pyrimido[1,2-a]pyrimidin-6-on-derivater
MX2009004884A (es) Derivados 8-piperidinil-2-piridinil-pirimido [1,2-a] pirimidin-6-ona y 8-piperidinil-2-pirimidinil-pirimido [1,2-a] pirimidin-6-ona sustuidos.
NO20064456L (no) Thiadiazolidinoner som GSK-3 inhibitorer
NO20092373L (no) Substituerte heteroarylpyridopyrimidonderivater
SG161217A1 (en) New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-alzheimer agents
MX2009006947A (es) Derivados de pirimidona 6-heterociclica 2-sustituida.
NO20064726L (no) Imidazolforbindelser for behandling av neurodegenerative forstyrrelser
NO20090749L (no) Arylaminoaryl-alkyl-substituerte imidazolidin-2,4-dioner, fremgangsmate for fremstilling derav, medikamenter inneholdende forbindelsene og deres anvendelse
BRPI0515851A (pt) composto de pirimidona
WO2009121535A3 (en) Antiproliferative compounds and therapeutic uses thereof
DE60335404D1 (de) Verwendung von 4-aminochinolin-verbindungen zur behandlung entzündlicher erkrankungen des auges
NO20063859L (no) Cykloalkylsubstituerte 7-amino-4-kinolon-3-karboksylsyrederivater, fremgangsmate for fremstilling derav og anvendelse derav som medikamenter
NO20054141L (no) 2-(diazabicykloalkyl)pyrimidonderivat, anvendelser derav for fremstilling av et medikament, medikament omfattende en slik forbindelse og mellomproduktforbindelse
ATE448214T1 (de) Neue 3-phenylpropionsäurederivate und ihre verwendung als ppar-gamma-rezeptorliganden
MX2009005242A (es) Derivados de 3-(hetero)arilisoquinolinamida sustituida en posición 5, 6 o 7 y uso terapeutico del mismo.
ATE480535T1 (de) Neue pyridoncarboxylsäurederivative oder salze daraus
TH74460A (th) อนุพันธ์ของ 8'-พิริ(มิ)ดินิล-ไดไฮโดรสไปโร-[ไซโคลอัลคิลามีน]-พิริมิโด[1,2-a]พิริมิดิน-6-โอน ที่ถูกแทนที่
TH82134B (th) อนุพันธ์ซับสทิทิวเทค 2-(ไอแอซา-ไบไซโคล-แอลคิล)-ไพริมิโดน
NO20063875L (no) Forbindelser som anvendes for behandling av sykdommer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application